Clinical Trials

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05675449 2026-04-13

MagnetisMM-20

59 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Other hematologic neoplasm

Multiple Myeloma, Recurrence

NCT02512926 2025-10-15

POE14-01

Phase 1 Completed

4 enrolled

Leukemia, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

43 enrolled

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

19 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

83 enrolled

Multiple Myeloma, Recurrence

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Phase 2 Completed

143 enrolled 14 charts

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase 1/2 Completed

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

8 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT03029234 2022-05-25

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Phase 3 Completed

126 enrolled 30 charts

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Phase 1/2 Completed

53 enrolled 17 charts

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT02187133 2021-04-23

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Completed

10 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT03512353 2021-01-08

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Phase 2 Terminated

7 enrolled 32 charts

Multiple Myeloma, Recurrence

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

18 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02042950 2019-05-01

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 2 Terminated

6 enrolled 6 charts

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02269085 2019-02-28

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

8 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02572492 2018-08-17

CARFI

Phase 2 Unknown

200 enrolled

Multiple Myeloma, Recurrence

NCT00511238 2017-08-31

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

312 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT02756663 2016-11-08

PANORAMA-5

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT02235740 2016-05-04

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

1 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn